https://thioredoxinreductas.co....m/index.php/anti-dsd
Most patients (~90%) received anti-EGFR mAbs with chemotherapy. Response rate (any reaction) was 41%. Median PFS was 4.3months with a median OS of 16M. Seven customers with infection control proceeded onto maintenance therapy (anti-EGFR mAb ± a fluoropyrimidine) with a median PFS of 13.8M. Next generation sequencing of 16 pts (28%) revealed 4 pts had a PIK3CA mutation with 3 of these 4 patients showing progress